 | 1 — 100 / 116 |  |
Drug Addiction
- LeClair Bissell (1994). Ethics for Addiction Professionals. Hazelden.
- Daniel Buchman & Peter Reiner (2009). Stigma and Addiction: Being and Becoming. American Journal of Bioethics 9 (9):18-19.
- Adrian Carter, Emily Bell, Eric Racine & Wayne Hall (2011). Ethical Issues Raised by Proposals to Treat Addiction Using Deep Brain Stimulation. Neuroethics 4 (2):129-142.
- Peter J. Cohen (2002). Untreated Addiction Imposes an Ethical Bar to Recruiting Addicts for Non-Therapeutic Studies of Addictive Drugs. Journal of Law, Medicine and Ethics 30 (1):73-81.
- Ezio Di Nucci (forthcoming). Addiction, Compulsion, and Agency. Neuroethics:1-3.
- David S. Festinger, Kattiya Ratanadilok, Douglas B. Marlowe, Karen L. Dugosh, Nicholas S. Patapis & David S. DeMatteo (2007). Neuropsychological Functioning and Recall of Research Consent Information Among Drug Court Clients. Ethics and Behavior 17 (2):163 – 186.
- Bennett Foddy (2011). Addicted to Food, Hungry for Drugs. Neuroethics 4 (2):79-89.
- Cynthia M. A. Geppert & Laura Weiss Roberts (eds.) (2008). The Book of Ethics: Expert Guidance for Professionals Who Treat Addiction. Hazelden.
- Carl L. Hart & Robert M. Krauss (2008). Human Drug Addiction is More Than Faulty Decision-Making. Behavioral and Brain Sciences 31 (4):448-449.
- Janna Hastings, Nicolas Le Novère, Werner Ceusters, Kevin Mulligan & Barry Smith (2012). Wanting What We Don’T Want to Want: Representing Addiction in Interoperable Bio-Ontologies. In Proceeedings of the Third International Conference on Biomedical Ontology. CEUR.
- Janna Hastings, Nicolas Le Novère, Werner Ceusters, Kevin Mulligan & Barry Smith (2012). Wanting What We Don’T Want to Want: Representing Addiction in Interoperable Bio-Ontologies. In Proceeedings of the Third International Conference on Biomedical Ontology. CEUR.
- Edmund Henden (forthcoming). Heroin Addiction and Voluntary Choice: The Case of Informed Consent. Bioethics.
- Joanna G. Katzman & Cynthia M. A. Geppert (2008). Ethical Dilemmas in Treating Chronic Pain in the Context of Addiction. In Cynthia M. A. Geppert & Laura Weiss Roberts (eds.), The Book of Ethics: Expert Guidance for Professionals Who Treat Addiction. Hazelden.
- Neil Levy (2006). Autonomy and Addiction. Canadian Journal of Philosophy 36 (3):427-447.
- Christian Perring (2002). Resisting the Temptations of Addiction Rhetoric. American Journal of Bioethics 2 (2):51-52.
- John Sarnecki, Rebecca Traynor & Michael Clune (2008). Cue Fascination: A New Vulnerability in Drug Addiction. Behavioral and Brain Sciences 31 (4):458-459.
- Sidney H. Schnoll & James Finch (1994). Medical Education for Pain and Addiction: Making Progress Toward Answering a Need. Journal of Law, Medicine and Ethics 22 (3):252-256.
Pharmaceuticals
- Matthias Adam (2005). Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry. Studies in History and Philosophy of Science Part C 36 (3):513-537.
- Henry Adobor (2012). Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry. Journal of Business Ethics 105 (2):239-255.
- Richard L. Allman (2003). The Relationship Between Physicians and the Pharmaceutical Industry: Ethical Problems with the Every-Day Conflict of Interest. HEC Forum 15 (2):155-170.
- Jonny Anomaly (2013). Collective Action and Individual Choice. Journal of Medical Ethics 39 (4).
- Edward R. Balotsky (2009). Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries. Journal of Business Ethics 84:75 - 88.
- David Barnard (2002). In the High Court of South Africa, Case No. 4138/98: The Global Politics of Access to Low-Cost AIDS Drugs in Poor Countries. [REVIEW] Kennedy Institute of Ethics Journal 12 (2):159-174.
- Amitrajeet A. Batabyal (2005). Book Review: Michael Kremer and Rachel Glennerster, Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Presss, Princeton, NJ and Oxford, UK. 2004. 153 Pp. Hb, ISBN: 0-691-12113-. [REVIEW] Journal of Agricultural and Environmental Ethics 18 (4).
- Stephanie Bell, Brad Partridge, Jayne Lucke & Wayne Hall (2013). Australian University Students' Attitudes Towards the Acceptability and Regulation of Pharmaceuticals to Improve Academic Performance. Neuroethics 6 (1):197-205.
- Nick Bostrom (forthcoming). Smart Policy: Cognitive Enhancement and the Public Interest. In Julian Savulescu, Ruud ter Muelen & Guy Kahane (eds.), Enhancing Human Capabilities. Wiley-Blackwell.
- Marcia M. Boumil, Emily S. Cutrell, Kathleen E. Lowney & Harris A. Berman (2012). Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers. Journal of Law, Medicine and Ethics 40 (2):311-325.
- Michael Boylan (2007). Medical Pharmaceuticals and Distributive Justice. Cambridge Quarterly of Healthcare Ethics 17 (01).
- Joan Buckley & Séamus Ó Tuama (2005). International Pricing and Distribution of Therapeutic Pharmaceuticals: An Ethical Minefield. Business Ethics 14 (2):127–141.
- William C. Buhles (2011). Compassionate Use A Story of Ethics and Science in the Development of a New Drug. Perspectives in Biology and Medicine 54 (3):304-315.
- D. M. Burley & T. B. Binns (eds.) (1985). Pharmaceutical Medicine. E. Arnold.
- A. Byrne (2000). Access to Experimental Drugs in Terminal Illness. Ethical Issues: Udo Schuklenk, New York, Pharmaceutical Products Press, 1998, 228 Pages, US$60. [REVIEW] Journal of Medical Ethics 26 (2):148-149.
- Laura Calkins (2010). Detained and Drugged: A Brief Overview of the Use of Pharmaceuticals for the Interrogation of Suspects, Prisoners, Patients, and Pows in the Us. Bioethics 24 (1):27-34.
- Philip J. Candilis (2000). Organizational Ethics and the High Cost of Medicines. HEC Forum 12 (4):303-310.
- Ashish Chandra & Gary A. Holt (1999). Pharmaceutical Advertisements: How They Deceive Patients. Journal of Business Ethics 18 (4):359 - 366.
- Pepe Lee Chang (2006). Who's in the Business of Saving Lives? Journal of Medicine and Philosophy 31 (5):465 – 482.
- Jillian Clare Cohen & Patricia Illingworth (2003). The Dilemma of Intellectual Property Rights for Pharmaceuticals: The Tension Between Ensuring Access of the Poor to Medicines and Committing to International Agreements. Developing World Bioethics 3 (1):27–48.
- Lindsay Cole, Jennifer Kesselheim & Aaron Kesselheim (2012). Ethical Issues in New Drug Prescribing. Journal of Bioethical Inquiry 9 (1):77-83.
- Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
- M. N. G. Dukes (2005). The Law and Ethics of the Pharmaceutical Industry. Elsevier.
- Brian D. Earp, Anders Sandberg & Julian Savulescu (2012). Natural Selection, Childrearing, and the Ethics of Marriage (and Divorce): Building a Case for the Neuroenhancement of Human Relationships. Philosophy and Technology 25 (4):561-587.
- Alexandre Erler (2012). One Man's Authenticity is Another Man's Betrayal: A Reply to Levy. Journal of Applied Philosophy 29 (3):257-265.
- Why the international market for pharmaceuticals fails & What to Do About It : A. Comparison of Two Alternative Approaches to Global Ethics (2008). Reflecting the Impact of Ethical Theory : Contractarianism, Ethics, and Economics. Christoph Luetge / Civilising the Barbarians? : On the Apparent Necessity of Moral Surpluses; Soeren Buttkereit and Ingo Pies / Social Dilemmas and the Social Contract; Peter Koslowski / Ethical Economy as the Economy of Ethics and as the Ethics of the Market Economy; Ingo Pies and Stefan Hielscher. In Jesús Conill Sancho, Christoph Luetge & Tatjana Schó̈nwälder-Kuntze (eds.), Corporate Citizenship, Contractarianism and Ethical Theory: On Philosophical Foundations of Business Ethics. Ashgate Pub. Company.
- David Finegold (ed.) (2005). Bioindustry Ethics. Elsevier Academic Press.
- Cynthia Forlini & Eric Racine (2009). Autonomy and Coercion in Academic “Cognitive Enhancement” Using Methylphenidate: Perspectives of Key Stakeholders. Neuroethics 2 (3).
- Jean-Paul Gaudillière (2005). Better Prepared Than Synthesized: Adolf Butenandt, Schering Ag and the Transformation of Sex Steroids Into Drugs (1930–1946). [REVIEW] Studies in History and Philosophy of Science Part C 36 (4):612-644.
- Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine and Ethics 40 (2):234-250.
- Robin Hanson, Warning Labels as Cheap-Talk: Why Regulators Ban Drugs.
- Willis W. Harman (1963). The Issue of the Consciousness-Expanding Drugs. Main Currents 20 (September-October):5-14.
- David Healy (2003). In the Grip of the Python: Conflicts at the University-Industry Interface. Science and Engineering Ethics 9 (1).
- Thomas A. Hemphill (forthcoming). Extraordinary Pricing of Orphan Drugs: Is It a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? Journal of Business Ethics.
- Laurence J. Hirsch (2002). Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc. Science and Engineering Ethics 8 (3).
- Ian Holliday (2003). Traditional Medicines in Modern Societies: An Exploration of Integrationist Options Through East Asian Experience. Journal of Medicine and Philosophy 28 (3):373 – 389.
- Gaudilliere J.-P. (2001). The Pharmaceutical Industry in the Biotech Century: Toward a History of Science, Technology and Business? Studies in History and Philosophy of Science Part C 32 (1):191-201.
- Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
- Thomas C. Jones (2005). A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care. Science and Engineering Ethics 11 (4):575-587.
- Guy Kahane (2011). Reasons to Feel, Reasons to Take Pills. In J. Savulescu, R. ter Meulen & G. Kahane (eds.), Enhancing Human Capacities. Wiley-Blackwell.
- Michiel Korthals & Cristian Timmermann (2012). Reflections on the International Networking Conference “Ethical and Social Aspects of Intellectual Property Rights – Agrifood and Health” Brussels, September 2011. Synesis 3:G66-73.
- Felicitas Kraemer (2011). Authenticity Anyone? The Enhancement of Emotions Via Neuro-Psychopharmacology. Neuroethics 4 (1):51-64.
- Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1).
- Rochelle Lee (2006). FDA and Drug Safety: New Tufts Study Challenges Critics of the Prescription Drug User Fee Act. Journal of Law, Medicine Ethics 34 (1):131-134.
- Donald W. Light & Joel Lexchin (2004). Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet. American Journal of Bioethics 4 (1):1 – 4.
- Peter R. Mansfield (2005). Banning All Drug Promotion is the Best Option Pending Major Reforms. Journal of Bioethical Inquiry 2 (2).
- Lawrence Masek (2006). Deadly Drugs and the Doctrine of Double Effect: A Reply to Tully. Journal of Business Ethics 68 (2):143-151.
- Lawrence Masek (2000). The Doctrine of Double Effect, Deadly Drugs, and Business Ethics. Business Ethics Quarterly 10 (2):483-495.
- Paul M. McNeill, Ian H. Kerridge, Catherine Arciuli, David A. Henry, Graham J. Macdonald, Richard O. Day & Suzanne R. Hill (2006). Gifts, Drug Samples, and Other Items Given to Medical Specialists by Pharmaceutical Companies. Journal of Bioethical Inquiry 3 (3).
- Paul T. Menzel (2010). Just Access to Health Care and Pharmaceuticals. In George G. Brenkert & Tom L. Beauchamp (eds.), The Oxford Handbook of Business Ethics. Oxford University Press.
- Ralph Metzner (2005). Psychedelic, Psychoactive, and Addictive Drugs and States of Consciousness. In Mitch Earleywine (ed.), Mind-Altering Drugs: The Science of Subjective Experience. Oxford University Press.
- Jennifer Moore (1989). Drug Testing and Corporate Responsibility: The “Ought Implies Can” Argument. Journal of Business Ethics 8 (4):279 - 287.
- Albert Mosley (2008). Global Pharmaceuticals: Ethics, Markets, Practices – Edited by Adriana Petryna, Andrew Lakoff and Arthur Kleinman. Developing World Bioethics 8 (2):162-164.
- Dale Murray & Heather Certain (2007). Pharmaceutical “Gift-Giving,” Medical Education, and Conflict of Interest. Journal of Philosophical Research 32:335-343.
- Saskia K. Nagel (2010). Too Much of a Good Thing? Enhancement and the Burden of Self-Determination. Neuroethics 3 (2).
- R. Stephen Parker & Charles E. Pettijohn (2003). Ethical Considerations in the Use of Direct-to-Consumer Advertising and Pharmaceutical Promotions: The Impact on Pharmaceutical Sales and Physicians. Journal of Business Ethics 48 (3):279-290.
- K. L. Phua & F. I. Achike (2007). Vioxx and Other Pharmaceutical Product Withdrawals: Ethical Issues in Ensuring the Integrity of Drug and Medical Device Research, Development and Commercialization. Clinical Ethics 2 (3):155-162.
- Ingo Pies & Stefan Hielscher (2011). The International Provision of Pharmaceuticals: A Comparison of Two Alternative Argumentative Strategies for Global Ethics. Journal of Global Ethics 7 (1):73 - 89.
- Toine Pieters & Stephen Snelders (2011). Standardizing Psychotropic Drugs and Drug Practices in the Twentieth Century: Paradox of Order and Disorder. Studies in History and Philosophy of Science Part C 42 (4):412-414.
- Toine Pieters & Stephen Snelders (2009). Psychotropic Drug Use: Between Healing and Enhancing the Mind. Neuroethics 2 (2).
- Rosa Lynn B. Pinkus (2002). From Lydia Pinkham to Bob Dole: What the Changing Face of Direct-to-Consumer Drug Advertising Reveals About the Professionalism of Medicine. Kennedy Institute of Ethics Journal 12 (2):141-158.
- Eric Racine & Cynthia Forlini (2010). Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs? Neuroethics 3 (1).
- A. Ravelingien, J. Braeckman, L. Crevits, D. De Ridder & E. Mortier (2009). 'Cosmetic Neurology' and the Moral Complicity Argument. Neuroethics 2 (3).
- Marc A. Rodwin (2011). Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan. Journal of Law, Medicine and Ethics 39 (4):662-670.
- Joakim Sandberg (2010). Ethics and the Pharmaceutical Industry. [REVIEW] European Journal of Health Law 17:211-214.
- Julian Savulescu, Ruud ter Muelen & Guy Kahane (eds.) (2011). Enhancing Human Capabilities. Wiley-Blackwell.
- R. G. Seigneuric, J.-L. Chassé, P. Auger & A. Bardou (2005). Simulated Interactions Between a Class III Antiarrhythmic Drug and a Figure 8 Reentry. Acta Biotheoretica 53 (4).
- Michael J. Selgelid (2008). A Full-Pull Program for the Provision of Pharmaceuticals: Practical Issues. Public Health Ethics 1 (2):134-145.
- David Shaw (2010). Homeopathy Is Where the Harm Is: Five Unethical Effects of Funding Unscientific Remedies. Journal of Medical Ethics 36 (3):130-131.
- David Shaw & David Conway (2010). Pascal’s Wager, Infective Endocarditis and the “No-Lose” Philosophy in Medicine. Heart 96 (1):15-18.
- Sergio Sismondo, Ghost Management: How Much of the Medical Literature is Shaped Behind the Scenes by the Pharmaceutical Industry?
- Sergio Sismondo, Pharmaceutical Maneuvers.
- Sergio sismondo, Linking Research and Marketing: A Pharmaceutical Innovation.
- Sergio Sismondo & Mathieu Doucet (2009). Publication Ethics and the Ghost Management of Medical Publication. Bioethics 24 (6):273-283.
- Jeremy Snyder (2010). Exploitations and Their Complications: The Necessity of Identifying the Multiple Forms of Exploitation in Pharmaceutical Trials. Bioethics 26 (5):251-258.
- Richard A. Spinello (1992). Ethics, Pricing and the Pharmaceutical Industry. Journal of Business Ethics 11 (8):617 - 626.
- Sigrid Sterckx (2005). Can Drug Patents Be Morally Justified? Science and Engineering Ethics 11 (1).
- Julie Tannenbaum (2013). The Promise and Peril of the Pharmacological Enhancer Modafinil. Bioethics 27 (3).
- Pepijn K. C. van de Pol & Frank G. A. de Bakker (forthcoming). Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility? Journal of Business Ethics.
 | 1 — 100 / 116 |  |
|
Off-campus access
Using PhilPapers from home?
Click here to configure this browser for off-campus access.
Monitor this page
Be alerted of all new items appearing on this page. Choose how you want to monitor it:
Email
|
RSS feed
|
|